Clinical and molecular characteristics of MET gene mutations in Azerbaijani patients with non-small cell lung cancer: a retrospective analysis
DOI:
https://doi.org/10.14739/2310-1210.2026.1.326859Keywords:
MET mutation, non-small cell lung cancer, real-time PCR, NGS confirmation, molecular diagnostics, AzerbaijanAbstract
Lung cancer is the leading cause of cancer-related mortality globally, with non-small cell lung cancer (NSCLC) accounting for approximately 85 % of all cases. The MET proto-oncogene has emerged as a critical molecular target due to its involvement in cellular proliferation, motility, and metastasis. Among MET alterations, exon 14 skipping mutations have gained significant clinical relevance as actionable biomarkers in NSCLC.
Aim: to determine the frequency and clinical characteristics of MET gene mutations in Azerbaijani patients diagnosed with NSCLC, and to provide a detailed descriptive analysis of mutation-positive cases.
Materials and methods. This retrospective study included 187 patients with histologically confirmed NSCLC treated at the National Oncology Center (Baku, Azerbaijan) between 2014 and 2024. MET mutation analysis was performed on formalin-fixed paraffin-embedded (FFPE) tumor samples using real-time polymerase chain reaction (PCR) with Qiagen and EntroGen reagents. All detected mutations were subsequently validated using next-generation sequencing (NGS). Descriptive statistics were used due to the limited number of mutation-positive cases (n = 16).
Results. MET gene mutations were identified in 16 out of 187 patients, representing a prevalence of 8.6 %. The mean age of MET-positive patients was 66.5 years (range: 53–84), with a male predominance (81 %). Most patients presented with advanced-stage disease (stage III–IV: 93.7 %), and adenocarcinoma was the predominant histological subtype (93.7 %). The median overall survival was 598 days. Tobacco use was reported in 56 % of cases, and alcohol consumption in 19 %. Patients originated from diverse regions of Azerbaijan, with the majority residing in
References
- Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi: https://doi.org/10.3322/caac.21763
| 
| 
- State Statistical Committee of the Republic of Azerbaijan. Cancer statistics report. 2025 [cited 2025 Dec 22]. Available from: https://www.stat.gov.az
- UNSCEAR 2020/2021 Report Volume I [Internet]. United Nations : Scientific Committee on the Effects of Atomic Radiation. [cited 2025 Dec 22]. Available from: https://www.unscear.org/unscear/en/publications/2020_2021_1.html
- Tong JH, Yeung SF, Chan AW, Chung LY, Chau SL, Lung RW, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of Non-Small Cell Lung carcinoma with poor prognosis. Clin Cancer Res. 2016;22(12):3048-56. doi: https://doi.org/10.1158/1078-0432.CCR-15-2061
| | - Paik PK, Drilon A, Fan PD, Yu H, Rekhtman N, Ginsberg MS, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5(8):842-9. doi: https://doi.org/10.1158/2159-8290.CD-14-1467
| | - Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383(10):944-57. doi: 10.1056/NEJMoa2002787
| | - Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020;383(10):931-43. doi: https://doi.org/10.1056/NEJMoa2004407
| | - Drilon A, Cappuzzo F, Ou SI, Camidge DR. Targeting MET in Lung Cancer: Will Expectations Finally Be MET? J Thorac Oncol. 2017;12(1):15-26. doi: https://doi.org/10.1016/j.jtho.2016.10.014
| | - Camidge DR, Otterson GA, Clark JW, Ignatius Ou SH, Weiss J, Ades S, et al. Crizotinib in Patients With MET-Amplified NSCLC. J Thorac Oncol. 2021;16(6):1017-29. doi: https://doi.org/10.1016/j.jtho.2021.02.010
| | - Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018;29(10):2085-91. doi: https://doi.org/10.1093/annonc/mdy334
| |
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Sabina Ganbar Mehdizadeh
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. 
